

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Alan Edward Tomkinson	03/12/2013
RECEIVING PARTY DATA	
Name:	The Regents of the University of New Mexico
Street Address:	1 University of New Mexico MSC05 3440
City:	Albuquerque
State/Country:	NEW MEXICO
Postal Code:	87131
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13783785
CORRESPONDENCE DATA	
Fax Number:	5052727300
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	lstanich@stc.unm.edu
Correspondent Name:	Lindsay Stanich
Address Line 1:	801 University Blvd. Suite 101
Address Line 4:	Albuquerque, NEW MEXICO 87106
NAME OF SUBMITTER:	Lindsay Stanich
Signature:	/Lindsay Stanich/
Date:	04/19/2013
Total Attachments: 2 source=2012-095-02 Assignment Inventor to UNM#page1.tif source=2012-095-02 Assignment Inventor to UNM#page2.tif	

OP \$40.00 13783785

INVENTOR ASSIGNMENT TO UNM

ASSIGNMENT from (inventor name): Alan Edward Tomkinson whose address is set forth on the signature page hereof (the "Inventor"), to the Regents of the University of New Mexico, an educational institution of the State of New Mexico, whose address is 1 University of New Mexico, MSC05-3440, Albuquerque, NM, 87131 (the "University").

WHEREAS, the Inventor, while employed by or enrolled at the University, conceived and/or reduced to practice one or more inventions which are described both in the disclosure described below and in other materials associated with the disclosure, including materials prepared after the date of this Assignment. The disclosure is identified as:

UNM Docket Ref. No.	Title
2012-095	Diagnostic Biomarkers to Identify Breast Cancer Patients Whose Disease will Respond to a Combination of DNA Ligase and PARP Inhibitors

(both the disclosure and the associated materials are collectively referred to herein as the "Invention Disclosure");

WHEREAS, one or more patent application(s) either have been or may be filed in the future in the United States Patent and Trademark Office and other patent offices covering the invention or inventions described in the Invention Disclosure (collectively, the "Patent Application(s)"). Any such patent application(s) filed as of the date hereof are described below:

Patent App. Serial No.	Country	Date of Filing	Title
13/783,785	US	3/4/2013	Targeting Abnormal DNA Repair In Therapy-Resistant Breast and Pancreatic Cancers

and

WHEREAS, the University is legally entitled to obtain a formal assignment from the Inventor of his/her entire right, title, and interest in and to invention(s) and related technology created by Inventor during his/her employment or enrollment by the University.

NOW, THEREFORE, the Inventor has individually and jointly agreed to assign and transfer and does hereby assign and transfer unto the University, its successors and assigns his/her entire right, title, and interest in and to: (a) the invention(s) described in the Invention Disclosure and/or Patent Application(s); (b) any technical information, know-how, trade secret, process, procedure, composition, biological materials, device, method, formula, protocol, technique, software, design, trade-name, trademark, copyright, copyrightable material, drawing or data which is related to the aforesaid invention(s) and/or that is included in the Invention Disclosure, whether or not covered by the Patent Application(s); (c) all rights of the Inventor in the Patent Application(s) including but not limited to all divisions, Letters Patent, reissues, re-examinations, continuations, continuations-in-part, continuing patent applications, substitutions, renewals, extensions filed and all patent(s) issuing thereon in the United States and all foreign countries, including but not limited to the right to apply for Letters Patent, Utility Models, or Inventor Certificates or equivalents in foreign countries in the Inventor's own name and to claim any priority rights for such foreign applications to which such applications are entitled under such countries' domestic laws, international conventions, treaties, or otherwise; and (d) to the extent the University owns the same under its policies and practices, all improvements to the invention(s) described in the Invention Disclosure and/or Patent Application(s) hereafter made or invented by the Inventor (all of the foregoing, (a), (b), (c), and (d) being collectively referred to throughout this Assignment as the "Invention"); and (e) the right to assert claims and bring lawsuits for any violation or infringement of any of the intellectual property rights assigned hereby, including all patents issuing on the Patent Applications.

The Inventor has individually and jointly already agreed and does hereby warrant for himself/herself and heirs, executors, and administrators, to execute and deliver without further consideration any further applications, assignments, and documents, and to perform such other acts as lawfully may be deemed necessary by the University, its successors, assigns, and nominees, fully to secure its right, title, and interest as aforesaid and to obtain and maintain Letters Patent, Utility Models, or Inventors' Certificates in any and all counties; and the Inventor hereby authorizes and requests the Commissioner of Patents to issue any and all Letters Patent which may be granted upon any of said applications, to the University as the assignee of the entire right, title, and interest therein.

THE INVENTOR FURTHER ACKNOWLEDGES AND AGREES AS FOLLOWS:

1. In accordance with the University's policies and practices, all net revenues from the Invention (all income received by the University, or its assignee, from commercialization of the Invention, not including payments for research, development or reimbursement of certain costs), shall be divided as follows: forty percent (40%) equally to the Inventors (unless the Inventors

